Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/jlb/lsaa060 http://scihub22266oqcxt.onion/10.1093/jlb/lsaa060 32913653!7472792!32913653     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Law+Biosci 2020 ; 7 (1): lsaa060 Nephropedia Template TP {{tp|p=32913653|t=2020. The problem with relying on profit-driven models to produce pandemic drugs |pdf=|usr=}}{{32913653}} gab.com Text The problem with relying on profit-driven models to produce pandemic drugs JO: J Law Biosci http://www.kidney.de/pget.php?&tw=1&pmid=32913653 #FOAvip In this article, we explain why profit-driven models for developing treatments for epidemic pathogens produce sub-optimal and sometimes negative public health outcomes. Using the example of the drug remdesivir, we demonstrate how the divergence of private incentives from public health needs has led to such outcomes during the COVID-19 pandemic. We conclude that policy responses to this and future pandemics ought to be conceived and designed in ways that narrow the divergence of private interests from public health needs, including through greater public-sector involvement in pharmaceutical R&D. Twit Text FOAVip The problem with relying on profit-driven models to produce pandemic drugs ????J Law Biosci http://www.kidney.de/pget.php?&tw=1&pmid=32913653 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32913653 #FOAvip English Wikipedia <ref>{{Cite pmid|32913653}}</ref> The problem with relying on profit-driven models to produce pandemic drugs #MMPMID32913653 Heled Y; Rutschman AS; Vertinsky L J Law Biosci 2020[Jan]; 7 (1): lsaa060 PMID32913653show ga In this article, we explain why profit-driven models for developing treatments for epidemic pathogens produce sub-optimal and sometimes negative public health outcomes. Using the example of the drug remdesivir, we demonstrate how the divergence of private incentives from public health needs has led to such outcomes during the COVID-19 pandemic. We conclude that policy responses to this and future pandemics ought to be conceived and designed in ways that narrow the divergence of private interests from public health needs, including through greater public-sector involvement in pharmaceutical R&D. äThe problem with relying on profit-driven models to produce pandemic d(epmc).pdf DeepDyve Pubget Overpricing